AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05912738 — intervention group
Intervention type: OTHER
Intervention: Interventional therapy
Description: Interventional therapy for postherpetic neuralgia includes nerve blocks, pulsed radiofrequency therapy, etc
Study NCT04762758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol
Description: oral fixed dose combination
Study NCT04762758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid oral solution
Study NCT05150106 — intervention group
Intervention type: OTHER
Intervention: Clinical assessments of laryngeal function
Description: Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM Naloxone Injection
Description: Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
Study NCT05514275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin and Capecitabine
Description: Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
Study NCT06231368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNCT19 CAR-T cell therapy
Description: CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
Study NCT04905810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT04905810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT04905810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02021474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGX-201
Description: Subcutaneous injection
Study NCT02021474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
Description: Subcutaneous injection
Study NCT05345704 — intervention group
Intervention type: OTHER
Intervention: cardiopulmonary resuscitation (CPR)
Description: Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
Study NCT04172376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive puncture aspiration plus rt-PA
Description: Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
Study NCT04172376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative medical treatment
Description: Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
Study NCT04290273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MED Test
Description: Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
Study NCT04290273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing device
Description: Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
Study NCT05939700 — intervention group
Intervention type: DRUG
Intervention: Mavacamten
Description: Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
Study NCT05815862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsule
Description: AL2846 is a multi-target tyrosine kinase inhibitor.
Study NCT06234085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCA feedback report available
Description: Access to feedback report described in the intervention
Study NCT06127472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training in detection and diagnosis of ASD
Description: To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
Study NCT06127472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PE program
Description: An adapted PE program for older adults with a recent diagnosis of ASD. The PE program consists of seven, two-hour group meetings on a weekly basis.
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Nasal Spray
Description: Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Swab
Description: 4 mg naloxone nasal swab administered in nostril
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Swab
Description: 8 mg naloxone nasal swab administered in nostril
Study NCT05013385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study NCT05013385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05451602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC169096
Description: Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
Study NCT06384300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
Study NCT06384300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
Study NCT06384300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Intervention
Description: Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
Study NCT05118750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-300 oral (PO) tablet
Description: One tablet daily
Study NCT05751252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
Study NCT05751252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
Study NCT06358976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration plus anti-spastic hand splint
Description: vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
Study NCT06358976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-spastic hand splint
Description: the use of anti-spastic hand splint alone.
Study NCT06358976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibration
Description: The use of hand vibrator alone
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Swab
Description: 12 mg naloxone nasal swab administered in nostril
Study NCT05363501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Swab
Description: 12.5 mg naloxone nasal swab administered in nostril
Study NCT06521385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Makani Science Respiratory Monitoring System
Description: Subjects monitored by the Makani Science Respiratory Monitoring System
Study NCT05105529 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
Study NCT05105529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
Study NCT05105529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Breathing 170ppb ozone
Study NCT05105529 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtere Air
Description: Breathing filtered air
Study NCT05471024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digitized Mounted Articulator Scan
Description: Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
Study NCT05471024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Average Positioning on Virtual Bonwill Triangle
Description: Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration.
Study NCT05471024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Face Scan
Description: Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration.
Study NCT04732780 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05116683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
Study NCT05772689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
Study NCT04933253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
Study NCT05772689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring While Black
Description: Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
Study NCT06471088 — intervention group
Intervention type: DRUG
Intervention: Dovprela
Description: Daily dose: 200 mg
Study NCT04739995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Description: 4.5 mg LDN/day for 1 year
Study NCT04739995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose naltrexone
Description: 4.5 mg LDN/day for 1 year
Study NCT05789914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap surgery+bone graft+guided tissue regeneration
Description: after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
Study NCT05789914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap surgery+bone graft+guided tissue regeneration
Description: after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
Study NCT04682795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-free injector
Description: Using needle-free injector as insulin carrier to treat T2DM
Study NCT04682795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pen
Description: Using insulin pen as insulin carrier to treat T2DM
Study NCT05920512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate extended-release tablets
Description: Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
Study NCT01894308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
Study NCT01894308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump Sprayer
Description: A dose of product solution is delivered by means of a metered pump spray.
Study NCT06074679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open cholecystectomy
Description: The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
Study NCT06074679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy
Description: The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
Study NCT05779631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI plus a same-day cystoscopic bladder biopsy
Description: mpMRI plus a same-day cystoscopic bladder biopsy
Study NCT05779631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURBT
Description: Transurethral resection of the bladder tumor
Study NCT05971875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES vs Vaginal Hysterectomy
Description: Comparison of vNOTES vs VH
Study NCT05971875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES vs Laparoscopic Hysterectomy
Description: Comparison of vNOTES vs LH
Study NCT05677269 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic excision of endometriosis, including colorectal endometriosis
Description: Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
Study NCT05711511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional obturation technique
Description: cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
Study NCT05711511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional obturation technique
Description: cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
Study NCT05711511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obtura II
Description: is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle
Study NCT05711511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Obtura II
Description: is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle
Study NCT04701606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artecom® (pyronaridine-artesunate)
Description: \* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)
Study NCT04701606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: \* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)
Study NCT05382806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil
Description: During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
Study NCT05382806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
Study NCT05299151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular exercises
Description: The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
Study NCT05299151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard neurorehabilitation exercises
Description: A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
Study NCT04638413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking (W)
Description: Participants engage in 30 min of walking daily, for three weeks.
Study NCT04638413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking + PolyRules! (W+PolyRules!)
Description: Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
Study NCT05371158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
Study NCT05677269 — intervention group
Intervention type: PROCEDURE
Intervention: In vitro fertilisation or intracytoplasmic sperm injection
Description: IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
Study NCT04421365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurofeedback brain-computer interface (BCI)
Description: The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.